Jane Huang
Overview
Jane Huang received an average of $2M in total compensation, including $469K in salary, at Prelude Therapeutics between 2022 and 2023. Jane Huang also received an average of $3M at BeiGene, Ltd. from 2017 to 2019.
Source: SEC filings on April 26, 2024, April 28, 2023, April 28, 2020, April 29, 2019, and April 30, 2018.
Related executives
We found 12 more executives who work or worked at Prelude Therapeutics and BeiGene, Ltd..
Krishna Vaddi
Prelude Therapeutics
Chief Executive Officer
Bryant Lim
Prelude Therapeutics
Chief Financial Officer
Peggy Scherle
Prelude Therapeutics
Chief Scientific Officer
Brian Piper
Prelude Therapeutics
Chief Financial Officer
Andrew Combs
Prelude Therapeutics
EVP and Head of Chemistry
John Oyler
BeiGene, Ltd.
Chief Executive Officer
Xiaobin Wu
BeiGene, Ltd.
General Manager of China and President
Howard Liang
BeiGene, Ltd.
Chief Financial Officer
News
Prelude Therapeutics CEO Krishna Vaddi's 2023 pay slips 20% to $2.6M
April 26, 2024
Prelude Therapeutics CEO Krishna Vaddi's 2022 pay falls 53% to $3.3M
April 28, 2023
BeiGene, Ltd. CEO John Oyler's 2019 pay falls 55% to $13M
April 28, 2020
BeiGene, Ltd. CEO John Oyler's 2018 pay jumps 171% to $28M
April 29, 2019